Evidence map›Paper›PMID 32388810›Full record

ArticleHuman cell2020

TRAF4 knockdown triggers synergistic lethality with simultaneous PARP1 inhibition in endometrial cancer.

Liulin Tang, Min Wang, Li Jiang, Chengying Zeng

Abstract read
PubMed Publisher
In one paragraph

Article in Human cell, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Liulin TangDepartment of Obstetrics and Gynecology, Affiliated Hospital of Guilin Medical University, Guangxi Zhuang Autonomous Region, Guilin City, 541001, China.
Min WangDepartment of Obstetrics and Gynecology, Affiliated Hospital of Guilin Medical University, Guangxi Zhuang Autonomous Region, Guilin City, 541001, China.
Li JiangDepartment of Obstetrics and Gynecology, Affiliated Hospital of Guilin Medical University, Guangxi Zhuang Autonomous Region, Guilin City, 541001, China.
Chengying ZengDepartment of Obstetrics and Gynecology, Guangdong Province, The Third Affiliated Hospital of Southern Medical University, No. 183 Zhongshan Avenue West, Tianhe District, Guangzhou City, 510630, China. ChengyingZengfkl@163.coma.
Guilin Medical University · CNThird Affiliated Hospital of Southern Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endometrial cancer (EC) is one of the most common cancers among females worldwide. Advanced stage patients of EC have poor prognosis. Inevitable side effects and treatment tolerance of chemotherapy for EC remain to be addressed. Our results in this study showed that EC cells with higher tumor necrosis factor receptor-associated factor 4 (TRAF4) expression have lower sensitivity to poly ADP-ribose polymerase 1 (PARP1) inhibitors. Upon TRAF4 knockdown, the colony numbers of EC cells were markedly down-regulated, and the markers of DNA double-strand breakage were significantly up-regulated after the treatment of olaparib, a PARP1 inhibitor. TRAF4 knockdown reduced the phosphorylation of protein kinase B (Akt), promoted DNA double-strand breakage, and decreased levels of DNA repair related proteins, including phosphorylated-DNA-dependent protein kinase (p-DNA-PK) and RAD51 recombinase (RAD51). In addition, TRAF4's effect on the sensitivity of EC cells to olaparib was further found to be mainly mediated by Akt phosphorylation. Moreover, in vivo results showed that TRAF4 knockdown enhanced the sensitivity of EC to PARP1 inhibitors using a mouse xenograft model. Collectively, our data suggest that combined application of TRAF4 knockdown and PARP1 inhibition can be used as a promising strategy for synthetic lethality in EC treatment.

Indexed as

Gene Knockdown TechniquesAnimalsAntineoplastic AgentsDisease Models, AnimalDNA Breaks, Double-StrandedEndometrial NeoplasmsFemaleGene ExpressionHumansMiceMolecular Targeted TherapyPhosphorylationPhthalazinesPiperazinesPoly (ADP-Ribose) Polymerase-1Proto-Oncogene Proteins c-aktAntineoplastic AgentsolaparibPARP1 protein, humanPhthalazinesPiperazinesPoly (ADP-Ribose) Polymerase-1Proto-Oncogene Proteins c-aktTNF Receptor-Associated Factor 4TRAF4 protein, humanAkt phosphorylationEndometrial cancerPARP1 inhibitorsSynthetic lethalityTRAF4

Identifiers

PMID32388810
OpenAlexW3022805262

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.